01—Abstract
Summary
Summary of the 8-K filed July 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences reported strong second-quarter 2025 results, with GAAP net sales of $1.53 billiona, up 11.9% year over year (10.6% on an adjusted, constant-currency basis).
Growth was broad-based: TAVR sales rose 8.9% to $1.13 billionb (7.8% constant currency), the TMTT franchise more than doubled its contribution with sales of $134.5 million (up 61.9%, driven by PASCAL and EVOQUE), and Surgical grew 7.7% to $267 million. Management said TAVR growth exceeded expectations, citing SAPIEN adoption, its asymptomatic-patient approval in the U.S., and a modest share gain in Europe after a competitor exited. Profitability was mixed.
Gross margin fell to 77.5%c from 79.9%, reflecting new-therapy manufacturing costs and foreign exchange. SG&A rose to 32.8% of sales and R&D fell to 18.0% of sales. GAAP operating margin was 26.8%, flat year over year, and 28.2% on an adjusted basis, helped by better-than-expected sales and deferred spending that management expects to hit the second half.
GAAP net income from continuing operations fell about 8% to $335.9 milliond because of a $47.1 million ($37.6 million after tax) impairment on a cost-method investment and a higher effective tax rate of 16.1% versus 5.2%. Adjusted diluted EPS was $0.67, and GAAP diluted EPS from continuing operations was $0.57. Edwards raised its full-year guidance: total sales growth to 9% to 10% ($5.9 billion to $6.1 billion), TAVR growth to 6% to 7% ($4.3 billion to $4.5 billion), and adjusted EPS to the high end of the original $2.40 to $2.50 range.
TMTT and Surgical sales guidance was unchanged. For Q3 2025, the company guided to sales of $1.46 billion to $1.54 billion and adjusted EPS of $0.54 to $0.60. Management also flagged higher second-half SG&A, partly tied to JenaValve, and said guidance assumes current tariffs remain in place.
02—Key points
Key Highlights
- Q2 2025 net sales of $1,532.2 million, up 11.9% GAAP and 10.6% adjusted/constant currency, with growth across all product groups and both U.S. (+10.3%) and outside-U.S. (+14.1%) regions.
- TAVR sales of $1,130.9 million, up 8.9% (7.8% constant currency), with stable global competitive position and pricing; Europe benefited modestly from a competitor's exit.
- TMTT sales of $134.5 million, up 61.9% (57.1% adjusted), driven by PASCAL and EVOQUE; SAPIEN M3 received CE Mark approval in Q2.
- Gross margin declined to 77.5% from 79.9%, due to expansion-related manufacturing costs and FX; operating margin held at 26.8% GAAP and 28.2% adjusted.
- GAAP net income from continuing operations fell about 8% to $335.9 million, weighed by a $47.1 million pre-tax impairment charge and a 16.1% effective tax rate (vs. 5.2%).
- Full-year guidance raised: total sales growth to 9% to 10%, TAVR growth to 6% to 7%, and adjusted EPS to the high end of $2.40 to $2.50; TMTT and Surgical guidance unchanged.
- Balance sheet remains strong with roughly $3 billion in cash and equivalents and about $600 million in total debt as of June 30, 2025; Q3 guidance calls for sales of $1.46 to $1.54 billion.
03—Questions
Frequently Asked Questions
Why did GAAP earnings decline even though sales grew nearly 12%?
GAAP net income from continuing operations fell to $335.9 million from $364.0 million. The main drivers were a $47.1 million ($37.6 million after tax) impairment on a cost-method investment, the effective tax rate rising to 16.1% from 5.2%, and a gross margin decline to 77.5% from 79.9%. Operating income actually rose about 12% to $411.2 million, so the decline is largely below the operating line and in tax.
What drove the guidance raise, and is it backed by the Q3 outlook?
Management attributed the raise to better-than-expected first-half performance and a strong TAVR outlook. The company now expects full-year sales of $5.9 billion to $6.1 billion and adjusted EPS at the high end of $2.40 to $2.50. For Q3, it guided to sales of $1.46 to $1.54 billion and adjusted EPS of $0.54 to $0.60, which is a sequential moderation from Q2's adjusted EPS of $0.67 and reflects the expected second-half spending increase.
How important is the TMTT business to the growth story?
TMTT is the fastest-growing product group, with Q2 sales of $134.5 million (up 61.9%) and year-to-date sales of $249.7 million (up 60.1%). Growth is driven by PASCAL and the EVOQUE tricuspid system, and SAPIEN M3 received CE Mark approval in Q2. TMTT is still small relative to TAVR's $1.13 billion quarterly sales, and management left its 2025 TMTT sales guidance unchanged.
What risks does the filing highlight?
The company noted that its guidance assumes currently effective or announced tariffs remain in place for the rest of 2025, and that any tariff changes could materially affect results. Margin pressure from new-therapy manufacturing expansion and foreign exchange, higher planned second-half SG&A (including spending related to JenaValve), and the cost-method investment impairment are also relevant. The filing also points to forward-looking-statement risks described in the 2024 Form 10-K.
What is the status of the Critical Care divestiture and discontinued operations?
Edwards recorded $4.2 million of separation costs in each of Q1 and Q2 2025 related to consulting, legal, tax, and advisory services for the sale of Critical Care. Results from discontinued operations were a loss of $4.4 million in Q2 2025, which is why GAAP diluted EPS including discontinued operations ($0.56) is slightly below EPS from continuing operations ($0.57). Management's reported numbers for continuing operations exclude these effects.
04—Continue